Business · 21/09/2001Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for Rescula Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the review period for Rescula's patent extension application, as mandated by law, following a submission to the US Department of Commerce's Commissioner of Patents and Trademarks.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →